3 articles | last updated: Jul 11 14:18:03
The Federal Trade Commission accuses PBMs of anti-competitive practices that increase patient costs and harm independent pharmacies.
- PBMs control nearly 80% of U.S. prescription drug distribution, leading to significant market power.
- The FTC alleges PBMs steer patients to affiliated pharmacies, often resulting in higher out-of-pocket costs.
- Rebates from drug manufacturers to PBMs can exclude cheaper generics, raising prices for consumers.
- Independent pharmacies struggle due to complex and opaque PBM contracts, contributing to closures.
- The FTC is considering legal action against major PBMs for their role in driving up medication costs.
People, Places and Things In This Story
- Federal Trade Commission Government agency
- United States Country in North America
Categories:
- Healthcare